Prerpints.org logo
Preprint
Review

Advances in Transdermal Drug Delivery Systems: a Bibliometric and Patent Analysis

Altmetrics

Downloads

132

Views

37

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

05 December 2023

Posted:

06 December 2023

You are already at the latest version

Alerts
Abstract
Transdermal drug delivery systems have become an intriguing research topic in healthcare technology and one of the most frequently developed pharmaceutical products in the global market. In recent years, researchers and pharmaceutical companies have made significant progress in developing new solutions in the field. This study sheds light on current trends, collaboration patterns, research hotspots, and emerging frontiers of transdermal drug delivery. Herein, a bib-liometric and patent analysis of data recovered from Scopus and The Lens databases, respectively, is reported over the last 20 years. From 2000 to 2022, the annual global publications increased from 131 in 2000 to 659 in 2022. Researchers in the United States, China, and India produced the highest number of publications. Likewise, most patent applications have been filed in the USA, China, and Europe. The recovered patents are 7,275, grouped into 2,997 patent families, of which 314 were granted. This study could support the work of decision-makers, scientific managers, or scientists to create new business opportunities or save money, time, and intellectual capital, thus, defining when a research or technology project should be a priority or not.
Keywords: 
Subject: Medicine and Pharmacology  -   Other

1. Introduction

Transdermal drug delivery (TDD) represents an alternative drug administration to oral delivery or hypodermic injection [1,2,3]. Since ancient times, people have placed substances or active molecules on the skin for their therapeutic effects and, in modern times, a variety of topical preparations have been developed to treat local medical conditions. In 1979, the first transdermal system for systemic delivery, treating motion sickness, was approved in the United States. Later, other drugs were approved for TDD (nicotine, estradiol, fentanyl, lidocaine, and testosterone), and different delivery systems (iontophoretic, ultrasonic, gels, patches, microneedles) were developed.
Aside from the oral route, TDD has several advantages [4] over hypodermic injections, which are invasive, painful, generate medical waste, pose a risk of disease transmission by needle reuse, especially in developing countries [5], and can’t be self-administered. TDD improves patient compliance and can provide a time-controlled release: it becomes especially important when drugs could be prematurely metabolized by the liver. Furthermore, these systems are generally inexpensive. However, high-molecular-weight drugs face significant limits in successful delivery due to the stratum corneum (SC). Therefore, several technologies have been developed to enhance the permeability of drugs across the SC, including chemical penetration enhancers, physical and electrical enhancement approaches, such as thermal ablation, electroporation, ultrasound, jet injection, and microneedles. These technologies provide a painless and controlled release of anti-inflammatories, vaccines, insulin, lidocaine, and other drugs. Therefore, due to the impact of TDD system on the patient’s health, research and development of new knowledge on these represent an urgent topic. In a state-of-the-art technological environment where convergence and dissemination are accelerated and the search for future technologies is an important issue, scientific and patent analysis is emerging as a central element. The bibliographic and patent scenario study in TDD can provide insights into the progress of technologies and knowledge involved in improving the patient’s life and help assess their use strategy. By analyzing both, papers and patents, researchers can make well-informed decision about target selection and priority.
Patents have long been regarded as essential incentives to promote innovation, due to the long, costly, and risky nature of the research and development process, particularly in the field of new drugs and delivery systems. The problem is further compounded by current statistics indicating a decrease in the number of new breakthrough drugs [6] despite the alleged surge in investments into pharmaceutical R&D. On the other hand, the number of new delivery systems of existing medicines is growing, demonstrating that pharmaceutical companies have been increasingly focusing their research on new devices, rather than on new drugs or other revolutionary innovations. Pharmaceutic companies invest in new drug delivery systems, including TDD, to extend products’ profitable lifecycles and provide patients with improved medications [7], guaranteeing competitive and financial advantages by administering drugs with new and innovative therapeutic benefits.
This paper presents an overview of bibliography and patents produced in academia and industry, through bibliometric and patent analysis. Bibliometric analysis can help identify trends in research, the journals publishing the most articles on this topic, and the countries producing the most research in this area. Patent analysis may allow the identification of stakeholders in TDD technologies and types of products or solutions being developed for the market. By comparing the two analyses, researchers and companies could collaborate in this field to develop new products. It is expected that this study could support the work of decision-makers, scientific managers, or scientists to create new business opportunities or save money, time, and intellectual capital, and define when a research or technology project should be a priority or not. This work begins with a focus of the scientific production on TDD followed by an analysis of patented technologies in the last 22 years (2000 – 2022). The analysis has been developed including co-occurrence and network analysis to summarize the progress in TDD and detect the hotspots or emerging trends and contributions of authors, journals, institutes, or countries using a specific data sample. The software VOSviewer has been used to develop a visual map of the co-occurrence between keywords and researchers. Furthermore, a network analysis based on the presence of keywords in papers and patents is developed. This analysis assumes that patents that share similar keywords are related in some way, and these relationships can be used to identify trends in innovation.

2. Materials and Methods

2.1. Bibliometric data collection and analysis

In this transversal study, the publication’s data was collected in a single day (February 24th, 2023) and downloaded as a csv file from Scopus (www.scopus.com). Information clustering and the outputs were performed with Excel’s programming functions. The proposed method is based on programming scripts to automatically obtain bibliographic data from scientific publications using the free Scopus Database API Interface, being Scopus the largest database of peer-reviewed literature in different scientific fields. The data sample development strategy is shown in Figure 1. The search terms were determined by the query ((TITLE-ABS-KEY(transdermal AND drug* AND delivery) AND PUBYEAR > 1999 AND PUBYEAR < 2023) AND ( LIMIT-TO ( DOCTYPE,"ar" ) ) ). Refining the search to articles (document type) published in the period between 2000 and 2022, information was collected, such as publications, authors, countries, institutions, founding sponsors, journals, keywords, and citations.
The recorded data were processed also by using bibliometric visualization software to extract and analyze publication data and create knowledge maps [8]. In the current study, we used VOSviewer (www.vosviewer.com) version 1.6.19 to obtain bibliographic information on researchers, research institutions, countries, citations, and keywords from Scopus csv files and to create network maps. Co-authorship and co-occurrence analysis were performed to identify the key themes and investigate hotspots in the literature. Co-authorship analysis reveals patterns of collaboration among countries [9]. Coexistence of keywords analysis uses the frequency of multiple words to identify their proximity, thus demonstrating hot topics and trends in the discipline. In this study, the top high-frequency keywords appearing in the retrieved publications were analyzed to explore hotspots in TDD research. In VOSviewer visualization maps, each node is represented by a labeled circle. Larger circles indicate a higher frequency in the co-occurrence analysis. The color of each circle is specific to the cluster to which it belongs. The thickness and length of links represent the strength of the connection between the corresponding nodes. A maximum of 1000 lines have been set to display the 1000 most robust links. VOSviewer was used to identify the cluster and the relationships among these clusters by the colored map [10], and to indicate the keywords that are covered by a cluster. Cluster interpretation may indicate trends and patterns in the research literature. By analyzing clusters of related keywords, researchers can gain insights into the most active research fields and identify potential areas of collaboration.

2.2. Patent data collection

On February 24th, 2023, a patents search was performed by using The Lens database (www.lens.org), with the following search string filling in the “Query Text Editor” field: (title:(transdermal) OR abstract:(transdermal) OR claim:(transdermal)) AND (title:(drug*) OR abstract:(drug*) OR claim:(drug*)) AND (title:(delivery) OR abstract:(delivery) OR claim:(delivery)). The Lens is a friendly database that accesses Espacenet, USPTO, WIPO, and Australian patent databases, being a broad-spectrum information retrieval tool. The search was limited to patents filed in the period between January 1st, 2000, and December 31st, 2022. The growth of TDD-related patents in 2000–2022 was analyzed, and the key origins (country), key owners, and classifications were examined. In addition, a network analysis based on keyword occurrence in patents has been developed. This analysis assumes that patents that share similar keywords are related. Clustering and information outputs were done using Excel, while the network analysis based on keywords occurrence of patents was developed with VOSviewer.

3. Results and discussion

3.1. Annual global publication on transdermal drug delivery

A total of 7,815 articles related to transdermal drug delivery research from 2000 to 2022 were recovered from Scopus. The production of annual publications on TDD is shown in Figure 2. Global annual publications increased from 131 in 2000 to 659 in 2022, with an average annual growth rate of 6.4 % and a maximum increase in 2020 (+28.8 %), probably because of the global pandemic emergency. As a response to the global health emergency, the scientific community has reallocated research programs to find innovative solutions and to prevent and fight COVID-19. The collected data support the hypothesis that this crisis has induced a sudden increase in research output in the areas of biomedical research, including TDD.
In contrast, in some years there was a stagnation in the number of papers published. The temporary lack of funding for R&D expenditure could explain this phenomenon. Research can be costly, and without adequate financial resources, it can be difficult for researchers to carry out their work. For example, in the 2010s, after the global financial crisis triggered by the bankruptcy of Brother Lehman Bank (2008), the growth of international production stopped, and this was first reflected in trade. Worldwide exports of goods and services, which had grown for decades, slowed down significantly relative to economic growth [11]. In the following years, the United States, Ireland, Spain, Greece, and many other European countries went into a deep recession. Driven by the economic downturn, global R&D spending fell [12]. This has led to fewer scientific findings and a slow decrease in the number of scientific publications. On the other hand, in some years an increase in the number of scientific publications could be related to the approval of new active molecules for TDD by the US Food and Drug Administration (FDA). The acceptance process for new drugs involves extensive research and testing to prove their safety and effectiveness. This research often leads to the production of new scientific knowledge, which can be disseminated through scientific publications. In addition, the approval of a new drug by the FDA can generate interest and further research in related areas, contributing to the increase in the number of scientific publications. For example, in 2006 three drugs were accepted by the FDA: Fentanyl HCl (Alza), Methylphenidate (Shire), and Selegiline (Bristol-Myers Squibb) [13]. Such approvals could have contributed to an increase in the publications in TDD in the subsequent years. The same phenomenon has been recorded when other active molecules for transdermal release have been approved [14,15].

3.2. Top 10 Journals and cited articles

The retrieved articles on TDD were published in 160 journals. Table 1 lists the top 10 journals that published the most articles on TDD, accounting for 26.5 % of the total publications. International Journal of Pharmaceutics was the most productive journal (525 publications) and the most highly cited journal (23,596 citations), followed by Journal of Controlled Release with 262 publications and Journal of Pharmaceutical Sciences with 226 publications.
Table 2 lists the top 10 most cited articles on TDD. “Biomedical applications of collagen" by Lee et al., published in International Journal of Pharmaceutics in 2001 [16] was the most cited article (1,516 citations), followed by “Penetration enhancers” by Williams et al., published in Advanced Drug Delivery Reviews [17]. A total of 6,995 articles were cited 208,512 times, with a median number of 29.8 citations.
Table 3 reports the top 10 authors who published papers on TDD, and their related affiliations.
In terms of the absolute number of publications on TDD, researchers in the United States, China and India produced the highest number [26]. The Figure 3 shows the top 100 countries that published papers on TDD.
Table 4 shows the top 10 funders such as government agencies or non-profit organizations. The US and China, by investing public funds in TDD research, have contributed significantly to the publication of scientific papers in this field. In the United States, funding comes from organizations like the National Institutes of Health (NIH), the National Institute of Biomedical Imaging and Bioengineering, and the National Science Foundation (NSF). In China, funding hails from agencies like the National Natural Science Foundation of China (NSFC) and the Ministry of Science and Technology (MOST).
Preprints 92333 g003
Figure 3. The top 100 countries in publishing papers on TDD.
Figure 3. The top 100 countries in publishing papers on TDD.
Preprints 92333 g003
The main subject areas derived from a bibliographic analysis on TDD (i.e., Pharmacology, Medicines, Biochemistry, Chemistry and Material Science) correspond to the issue of research activities carried out on this field (Table 5).

3.3. Co-authorship of countries

It is widely recognized that there is a great interest in health research and the TDD is one of the most appealing areas. The results showed that a total of 100 countries contributed to TDD research, as shown in Figure 3. USA (1,529 publications) is the most productive country, followed by China (1,371), India (1,325), United Kingdom (486), South Korea (439), Japan (396), Egypt (297), Germany (290), Italy (248) and Saudi Arabia (195). VOSviewer was used for co-authored country analysis to show links of international collaborations on TDD (Figure 4). In the network visualization, countries are represented by circles; for some minor countries the symbol cannot be showed, to avoid overlapping. The 1,000 strongest links are displayed by lines. In this visualization the distance between two countries approximately indicates their relatedness in terms of co-authorship links. The closer two countries are located to each other, the stronger their relatedness.
The network, including 65 countries, was defined by 8 differently colored clusters, connected to each other through co-authorship links. The largest cluster (red), consisting of 19 countries, 3,275 articles and 117,835 citations, is centered on the United States, Germany, Italy, and France. The US have the most significant number of cooperating partners (51). China, Australia, and South Korea are part of the second largest cluster (green), consisting of 8 countries, 3,240 articles and 51,557 citations. India is the center of the blue-sky cluster (third in size) consisting of 5 countries, 1,420 articles and 28,195 citations.

3.4. The co-occurrence analysis of the top keywords

Co-occurrences indicate the number of documents in which a keyword occurs. Keywords in research papers define the research topic and are used to make the scientific article more detectable. In this study, VOSviewer extracted and clustered the top 92 keywords, as shown in Table 6.
Figure 5 shows a network map of the top keywords in six clusters with their co-occurrence, represented by a circle. The size of the circle is determined by the frequency of the Keywords: Lines between keywords represent links, of which the strongest 1,000 are displayed. The keywords transdermal (958), iontophoresis (398), drug delivery (379), skin (332), and microneedle (295) are placed at the center of the network. All keywords were grouped into 6 main clusters and displayed by red (cluster 1), green (cluster 2), blue (cluster 3), yellow (cluster 4), purple (cluster 5) and blue-sky (cluster 6) circles.
Cluster 1 - in red - represents different studies that examined the skin absorption of commercially available topical nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., diclofenac, ibuprofen) [27,28], modified formulations to obtain superior anti-inflammatory activity [29]. The therapeutic effect of NSAIDs depends on the drug’s ability to penetrate and permeate the skin [30]. Recent studies have investigated the use of transdermal delivery of NSAIDs for the treatment of inflammatory diseases, such as rheumatoid arthritis and osteoarthritis [31,32]. Studies have shown that transdermal delivery of NSAIDs could offer several advantages over oral administration, including improved bioavailability, reduced systemic exposure, and lower risk of gastrointestinal adverse effects [33]. Other recent studies have investigated the use of transdermal delivery of anti-inflammatory molecules for the treatment of psoriasis [34]. The studies demonstrated that transdermal delivery of the biological molecules could reduce inflammation and improve skin barrier function [35].
Cluster 2 - in green – mainly represents the TDD application in pain management [36]. Fentanyl and buprenorphine are opioid analgesics that are commonly used to treat moderate to severe pain [37]. Both drugs have a high potency, which means that they can be effective at lower doses than other opioids [38]. Transdermal administration of these drugs may provide a more consistent and predictable delivery than oral administration, which may lead to better pain control and fewer side effects. Lidocaine is a local anesthetic that can be used to relieve pain in a specific area [39]. Transdermal delivery of lidocaine has been investigated for the treatment of chronic pain conditions such as neuropathic pain and post-herpetic neuralgia. Lidocaine patches can provide long-lasting pain relief with fewer side effects compared to systemic administration. Estradiol is a hormone that has been investigated for the treatment of menopausal symptoms such as hot flashes. However, it has also been studied for its potential analgesic effects in the treatment of pain [40]. Transdermal delivery of estradiol can provide a sustained release of the drug, which may lead to improved pain control and less side effects then oral administration. The design of transdermal drug delivery systems and the factors affecting drug permeation, bioavailability and pharmacokinetics are important considerations in the development of these systems [41].
Cluster 3 - in blue - represents the papers on the importance of skin permeability, diffusion, and absorption in the transdermal drug delivery, as well as the use of permeation enhancers, hydrogels, and other formulations to improve drug delivery. They also provide insights into mathematical models and strategies for enhancing drug solubility and permeability. For example, Mitragotri et al. describe mathematical models used to predict drug permeation across the skin [42], including factors such as solubility, diffusion, and permeability enhancers. Prausnitz et al. discuss the challenges of providing proteins through the skin [43] and various strategies to improve their absorption, including the use of permeation enhancers, hydrogels, and other formulations. Williams et al. examine various classes of permeation enhancers [17] used to improve drug absorption through the skin, including surfactants, solvents, and other chemicals. In addition, vesicular systems are studied to be used to deliver vaccines through the skin, which is a promising route for vaccination due to the abundance of antigen-presenting cells in the skin [44]. For example, niosomes have been used to administer hepatitis B vaccine [45]. Vesicular systems are also studied for gene delivery through the skin, which is a non-invasive and painless approach to gene therapy [46]. For example, liposomes have been used to deliver siRNA for the treatment of skin diseases, such as psoriasis.
Cluster 4 - in yellow - represents some studies on the development of nanoparticles as a delivery system for TDD applications. In this research, chitosan plays an important role [47] for TDD due to their unique properties, such as biocompatibility, biodegradability, and mucoadhesiveness. Chitosan nanoparticles have several advantages in transdermal drug delivery, such as improved drug permeation and bioavailability, prolonged drug release, and reduced skin irritation. Nanoparticles can also protect the drug from degradation and enhance its stability. Additionally, chitosan nanoparticles can be functionalized with various molecules, such as permeation enhancers and targeting ligands, to further improve their efficacy in TDD. Several studies have investigated the use of chitosan nanoparticles for transdermal delivery of various drugs, including antihypertensives [48], anti-inflammatory agents, and anticancer drugs [49]. Also in vitro and in vivo studies have demonstrated the potential of chitosan nanoparticles for transdermal delivery of these drugs [50], showing improved permeation and bioavailability compared to conventional formulations. However, there are still some challenges associated with the use of chitosan nanoparticles in TDD, such as poor stability under certain conditions, low drug loading capacity, and potential toxicity issues [47].
Cluster 5 - in purple - represents methods and techniques to optimize the drug delivery of micro and nanoparticles into the skin. The keywords of this cluster, iontophoresis [51], microneedles [18], sonophoresis [52], electroporation [53], and ultrasound [54] are all techniques that can be used to enhance TDD, including drugs such as insulin [55] used to treat diabetes. The combination of these techniques can further increase drug permeation and effectiveness and may offer potential alternatives to traditional injection-based therapies.
Cluster 6 - in blue-sky – mainly represents applications of vesicular delivery systems as carriers in TDD applications [56]. Different types of vesicular drug delivery systems have been reported as keywords, such as bilosomes, pharmacosomes, emulsomes, transfersomes, liposomes, and niosomes. Vesicular delivery systems are widely used as carriers in TDD due to their ability to enhance drug penetration across the skin. Recovered studies report that these systems can improve drug solubility, stability, and bioavailability, as well as reduce systemic toxicity and increase therapeutic efficacy. In general, liposomes are spherical structures composed of a lipid bilayer that can encapsulate hydrophilic or hydrophobic drugs. Niosomes are like liposomes but are composed of non-ionic surfactants. Transfersomes are highly deformable lipid vesicles that can penetrate the SC of the skin more efficiently than liposomes and niosomes. For example, transfersomes have been used to deliver hormones [57], such as testosterone and estradiol for hormone replacement therapy.
In Table 7 are reported some examples of articles included in the above-mentioned clusters.

3.5. Patent database analysis

The total number of recovered patents includes 7,275 documents grouped into 2,997 patent families, of which 314 granted. A total of 110 distinct applicants were found. In the retrieved database, 152 documents were cited more than 100 times (highly cited patents). The number of citations measures the importance of a patent and highly cited patents are precursors that best define the state of the art, indicating the level of influence that patent has had on subsequent inventions. Indexing citation is an important tool for evaluating the value and impact of a patent. Patents with high citation indexes are more likely to be licensed or sold at a higher price, as they are seen as more innovative and influential in their field. The document US 8 617 071 B2 “Analyte monitoring device and methods of use” [69], with 1,197 citations, was the most cited by the other patent documents. This patent, filed in 2000 and owned by Abbott Diabetes Care Inc, describes an electrochemical sensor-based device for analyte monitor that is also part of a TDD system to alter the analyte level, based on the data obtained using the sensor. It is important to stress that technologies considered essential could mentioned more times. In addition, older patents are cited more often simply because they have had more opportunities to be cited, while new applications could take more time to be found out by other players and be cited. By understanding the level of influence and impact of a specific patent, businesses and researchers can make informed decisions about how to invest their resources and develop research activities.
Since the World Intellectual Property Organization (WO) application is related to an undefined place for protection, these results will be excluded from the potential markets for the exploitation of technologies analysis. According to Table 8 that report the top 10 countries in which patents have been filed or granted, the US was preferred to apply technologies related to TDD. The high number of biotech companies could be a substantial factor influencing applicants’ interest. China, still according to Table 8, is a place with considerable interest by the patent applicants on TDD. The Chinese patent office was preferred over the European Patent Office.
The evolution of the number of patent applications through the years is shown in Figure 6.
One way to analyze this growth of patent applications is by an S-curve. Expanding the time range of number application, from 1980 to 2022, the S-curve shows three stages: an initial slow growth phase, followed by a rapid acceleration phase, and finally, a saturation phase in which growth stabilizes [70]. This graph represents the growth of TDD technology and the rate with which new solutions are invented and patented. During the early stages of technological development, the growth of patent applications is slow, due to the rarity of new technologies and the limited innovation background. However, as more and more individuals and organizations focus on developing new technologies, the number of patent applications gradually increases, leading to the acceleration phase of the S-curve. At this stage, the rate of growth of patent applications noses up as more people and companies apply for patents to protect their inventions. The acceleration phase is characterized by a sharp increase in the rate of change of patent applications (2002-2004). Eventually, the growth rate of patent applications reaches a plateau during the saturation phase as most of the new technologies have been invented, causing a slowdown in the rate of innovation. This plateau is achieved in the period 2004 - 2020. Considering that patent applications are usually published 18 months after the filing date, the number of applications in the last year and a half of the analyzed period (2021 – 2022) could be underestimated in Figure 6.
As shown in Table 9, the most common Cooperative Patent Classification (CPC), A61K, concerns “devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms”, “materials for disinfection or sterilization, or for bandages, dressings, absorbent pads”. These CPCs adequately describe the retrieved patent database.
The ten most active patent applicants are listed in Table 10, where United States companies are the major players in the patenting activities of TDD technologies.
The low presence of universities in the top ten applicants probably indicates that most of the TDD technologies are mature enough to be fully explored by companies. Often, academic patents are filed for academic purposes and not for commercial reasons [71,72]. A very singular case, widely studied is that of microneedles technology [73], which has generated numerous papers, patents, and clinical studies. The field of microneedles is widely patented by universities, and it has excellent potential in the transdermal delivery of innovative products to improve health, and quality of life.
Another intriguing aspect observed when examining patents is that, despite a substantial increase in the amount of research publications related to TDD in India, there has been a relatively low number of patents filed in this country. This phenomenon may be due to a lack of resources and expertise in patent filing among Indian researchers.
Table 10. Top 10 applicants in TDD field.
Table 10. Top 10 applicants in TDD field.
Applicant Name % documents Country
Noven Pharma 4.3 USA
Alza Corp 3.1 USA
3M Innovative Properties Co 2.0 USA
Univ California 1.0 USA
Acrux Dds Pty LTD 1.0 Australia
Mylan Technologies INC 0.9 USA
Kimberly Clark Co 0.9 USA
Corium Int INC 0.8 USA
Chrono Therapeutics INC 0.8 USA
Koninkl Philips Electronics Nv 0.7 Holland
Noven Pharmaceuticals (NP), the first TDD patent candidate, is a Miami-based pharmaceutical company specializing in the developing and marketing of innovative therapies for central nervous system (CNS) disorders (www.noven.com). As shown in Table 10, the company has a strong patent strategy to protect its intellectual property (IP) and maintain its competitive edge in the market. NP’ patent portfolio includes a mix of both product and process patents. This allows the company to protect its drug products and the manufacturing processes and formulations used to produce them. The company’s IP resources are focused on its core areas of expertise, including CNS disorders therapies. NP has also partnered with various pharmaceutical companies to develop and market TDD systems. Some of the commercial products that have been developed using NP drug delivery technologies include: i) Daytrana - a transdermal patch for the treatment of attention deficit hyperactivity disorder (ADHD), developed in association with Shire Pharmaceuticals (https://www.daytrana.com) - ii) Minivelle - a transdermal patch for the treatment of menopausal symptoms, developed in collaboration with Novartis Pharmaceuticals (www.noven.com/products/minivelle ) - iii) Butrans - a transdermal patch for the treatment of chronic pain, developed in partnership with Purdue Pharma (www.butrans.com). In Table 10, Azla Corporation (AC) is in second place. AC is a private biopharmaceutical company specializing in the development of TDD technologies (www.azlacorp.com) that has filed patent applications for a few pertinent technologies and methods, including patches, gels, and other delivery systems. Furthermore, it has developed and patented some technologies related to i) microneedle patches, ii) transdermal gel formulations, iii) controlled-release transdermal patches.

3.6. The co-occurrence analysis of the top keywords of recovered patents

The correlation of keywords was calculated by counting the frequency of their occurrence together in the titles and patent abstracts. A co-occurrence network was created by VOSviewer. For each keyword, the total strength of the co-occurrence links with the other ones was evaluated (Figure 7A). The overlay visualization, shown in Figure 7B, differs graphically from the network view (Figure 7A) for differently colored keywords. In Figure 7B, the color of a keyword is determined by the patent application date, which contains it: colors range from blue (older patents) to green to yellow (newer patents). In the overlay visualization, the latest yellow-colored patents, for example, are related to the area of microneedle technologies.
Microneedle technologies have been subject of academic and industrial researchers’ intensive research and development efforts. Thus, the number of patents describing microneedles as novel minimally invasive devices for drug delivery purposes has grown exponentially in recent years [74].
In Figure 8, keywords with the highest total link strength have been selected and reported. The total link strength obtained from co-occurrence networks indicates the number of patents in which two keywords occur together. Here, a stronger link typically indicates a higher frequency of the two keywords appearing together in patents.
Analysing the keywords with the highest total link strength, the main topics of patents on TDD applications include: housing (9,469)[13], microneedle (6,022), cancer (5,065), sensor (4,683), prodrug (4,262), imiquimod (3,896), nutraceutical (3,720), protocell (3,610), therapy (3,519) and beneficial substance (3,410). These keywords are placed at the center of the network represented in Figure 7A. The closer the keywords are to each other, the stronger their relationship is. Housing, sensor, and microneedle, which are close in the network, refer to medical devices for TDD. Some patents describe a transdermal drug delivery device that includes a housing to contain a reservoir of drug and a microneedle array for drug delivery through the skin. Table 11 lists the most cited active patents that refer to a medical device, reporting information on active patent applications, filed in the last 20 years, including the application number, application date, title, owners, and representative figure or scheme. The device can also include a sensor, such as a biosensor, to monitor drug levels in real-time and ensure accurate dosing. The sensor may be integrated into the housing or positioned near the microneedle array for efficient monitoring Furthermore, the device can also include a controller, which may be in the housing or in a separate unit, to adjust the drug administration according to the sensor readings. This combination of a microneedle array, drug reservoir, sensor, and controller in one housing provides a convenient and effective TDD system for various medical issues.
A list of the top cited patents that refer to TDD solutions for cancer treatment, and administration of prodrugs are reported in Table 12 and Table 13, respectively.

4. Conclusion

This paper proposes an overview of the last twenty years of publications and patents about TDD to identify and compare main functions, application fields, and technological aspects. The main novelty concerns the use of both papers and patents, to provide a comparative perspective on how the frontier of knowledge is advancing in the field of TDD. The distribution of scientific papers is growing constantly, while the number of patents filed per year is constant, as shown in Figure 9, except for the last two years, since patents from the first 18 months are not disclosed.
This is because the scientific community has invested more resources in research and study of TDD solutions, leading to more publications. Research in this field has moved towards developing of new formulations and technologies capable of overcome the limitations of the transdermal delivery route. However, these studies may not necessarily involve the submission of new patents, as some of the innovations may not meet the patentability criteria or may not be considered commercially viable. Moreover, the scientific publications could be considered prior art, which means that they can prevent the patentability of subsequent inventions that are not sufficiently different from them. Additionally, some of the research in TDD field focuses on fundamental scientific understanding rather than practical applications. Furthermore, the patent landscape for TDD has become more crowded, making it more difficult for patenting.
Bibliometric and patent analysis, despite a partial overlap between technological trends in the TDD developed in scientific articles and those reported in the patent, shows some important differences. In scientific papers, key technological trends in TDD include: (i) the development of new materials and formulations that improve drug permeation and skin penetration, such as lipid-based systems and hydrogels (cluster 1, cluster 3, cluster 4, cluster 6); (ii) the development of physical methods to enhance drug delivery, such as microneedles, ultrasound, and iontophoresis also for the treatment of diabetes (cluster 5); (iii) the development of TDD systems for a wider range of drug classes, including NSAIDs, pain management, biologics and hormones (cluster 1, cluster 2). Some of the key technological trends reported in patents on TDD are: (i) novel devices and methods to enhance drug delivery and achieve targeted drug release profiles; (ii) the use of TDD for new applications, such as the delivery of gene therapies and immunotherapies; the development of new manufacturing methods and technologies to improve the scalability and reproducibility of TDD systems.
Overall, the patent landscape tends to be more focused on specific products and applications such as wearable devices, nanocarriers to increase drug permeability and new formulations. In contrast, scientific research tends to be more exploratory and focused on developing a deeper understanding of the underlying science and mechanisms of transdermal drug delivery.

Author Contributions

Conceptualization, A.C., S.D.I., C.M. and L.N.; methodology, A.C.; software, A.C.; validation, A.C., S.D.I..; formal analysis, A.C.; investigation, A.C..; resources, A.C..; data curation, A.C..; writing—original draft preparation, A.C. and S.D.I..; writing—review and editing, A.C. and S.D.I.; visualization, A.C. and S.D.I.; supervision, A.C., C.M. L.N..; project administration, A.C., C.M., and L.N..; funding acquisition, C.M., and L.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data are available on request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Transdermal Drug Delivery; Guy, Richard H.; Hadgraft, J., Ed.; 2nd ed.; New York - Basel, 2003; ISBN 082470861X.
  2. Williams, A. Transdermal and Topical Drug Delivery from Theory to Clinical Practice; Pharmaceutical Press, 2003; ISBN 9780853694892.
  3. Prausnitz, M.R.; Mitragotri, S.; Langer, R. Current Status and Future Potential of Transdermal Drug Delivery. Nat. Rev. Drug Discov. 2004, 3, 115–124. [CrossRef]
  4. Percutaneous Absorption; Bronaugh, R. L.; Maibach, H.I., Ed.; 2005; Vol. 155; ISBN 9780429186493.
  5. Miller, M.A.; Pisani, E. The Cost of Unsafe Injections. Bull. World Health Organ. 1999, 77, 808–811.
  6. Pammolli, F.; Magazzini, L.; Riccaboni, M. The Productivity Crisis in Pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 10, 428–438. [CrossRef]
  7. Novel Drug Delivery Technologies Innovative Strategies for Drug Re-Positioning; Misra, A.; Shahiwala, A., Ed.; 2019; ISBN 978-981-13-3641-6.
  8. Eck, N.J.; Waltman, L. Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping. Scientometrics 2010, 84, 523–538.
  9. Newman, M.E.J. Coauthorship Networks and Patterns of Scientific Collaboration. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5200–5205. [CrossRef]
  10. van Eck, N.J.; Waltman, L. Citation-Based Clustering of Publications Using CitNetExplorer and VOSviewer. Scientometrics 2017, 111, 1053–1070.
  11. Zhan, J.X. GVC Transformation and a New Investment Landscape in the 2020s: Driving Forces, Directions, and a Forward-Looking Research and Policy Agenda. J. Int. Bus. Policy 2021, 4, 206–220. [CrossRef]
  12. Naqeeb Ur Rehman, E.H.; Mao, X. Does Public R\&D Complement or Crowd-out Private R\&D in Pre and Post Economic Crisis of 2008? J. Appl. Econ. 2020, 23, 349–371. [CrossRef]
  13. Prausnitz, M.R.; Langer, R. Transdermal Drug Delivery. Nat. Biotechnol. 2008, 26, 1261–1268. [CrossRef]
  14. Bird, D.; Ravindra, N.M. Transdermal Drug Delivery and Patches—An Overview. Med. DEVICES \& SENSORS 2020, 3, e10069. [CrossRef]
  15. Liu, P.; Chen, G.; Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules 2022, 27. [CrossRef]
  16. Lee, C.H.; Singla, A.; Lee, Y. Biomedical Applications of Collagen. Int. J. Pharm. 2001, 221, 1–22. [CrossRef]
  17. Williams, A.C.; Barry, B.W. Penetration Enhancers. Adv. Drug Deliv. Rev. 2012, 64, 128–137. [CrossRef]
  18. Prausnitz, M.R. Microneedles for Transdermal Drug Delivery. Adv. Drug Deliv. Rev. 2004, 56, 581–587. [CrossRef]
  19. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes — Novel Vesicular Carriers for Enhanced Delivery: Characterization and Skin Penetration Properties. J. Control. Release 2000, 65, 403–418. [CrossRef]
  20. Park, J.-H.; Allen, M.G.; Prausnitz, M.R. Biodegradable Polymer Microneedles: Fabrication, Mechanics and Transdermal Drug Delivery. J. Control. Release 2005, 104, 51–66. [CrossRef]
  21. Lee, H.; Song, C.; Hong, Y.S.; Kim, M.; Cho, H.R.; Kang, T.; Shin, K.; Choi, S.H.; Hyeon, T.; Kim, D.-H. Wearable/Disposable Sweat-Based Glucose Monitoring Device with Multistage Transdermal Drug Delivery Module. Sci. Adv. 2017, 3, e1601314. [CrossRef]
  22. McAllister, D. V; Wang, P.M.; Davis, S.P.; Park, J.-H.; Canatella, P.J.; Allen, M.G.; Prausnitz, M.R. Microfabricated Needles for Transdermal Delivery of Macromolecules and Nanoparticles: Fabrication Methods and Transport Studies. Proc. Natl. Acad. Sci. 2003, 100, 13755–13760. [CrossRef]
  23. Kalia, Y.N.; Naik, A.; Garrison, J.; Guy, R.H. Iontophoretic Drug Delivery. Adv. Drug Deliv. Rev. 2004, 56, 619–658. [CrossRef]
  24. Lee, J.W.; Park, J.-H.; Prausnitz, M.R. Dissolving Microneedles for Transdermal Drug Delivery. Biomaterials 2008, 29, 2113–2124. [CrossRef]
  25. Cevc, G. Lipid Vesicles and Other Colloids as Drug Carriers on the Skin. Adv. Drug Deliv. Rev. 2004, 56, 675–711. [CrossRef]
  26. Chen, X.; Xiao, H.; Zhao, Q.; Xu, X.; Cen, Y.; Xiao, D. Research Hotspot and Trend of Microneedles in Biomedical Field: A Bibliometric Analysis from 2011 to 2020. Burns 2022, 48, 959–972. [CrossRef]
  27. Rasool, B.K.A.; Abu-Gharbieh, E.F.; Fahmy, S.A.; Saad, H.S.; Khan, S.A. Development and Evaluation of Ibuprofen Transdermal Gel Formulations. Trop. J. Pharm. Res. 2010, 9, 355–363. [CrossRef]
  28. Pradal, J. Comparison of Skin Permeation and Putative Anti-Inflammatory Activity of Commercially Available Topical Products Containing Ibuprofen and Diclofenac. J. Pain Res. 2020, 13, 2805–2814. [CrossRef]
  29. Benbow, T.; Campbell, J. Microemulsions as Transdermal Drug Delivery Systems for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Literature Review. Drug Dev. Ind. Pharm. 2019, 45, 1849–1855. [CrossRef]
  30. Kumar, L.; Verma, S.; Singh, M.; Chalotra, T.; Utreja, P. Advanced Drug Delivery Systems for Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs: A Review. Curr. Drug Deliv. 2018, 15, 1087–1099. [CrossRef]
  31. Panpan Xie Wei Xue, W.Q.Y.L.L.Y.Z.Y.; Shi, A. Safety, Tolerability, and Pharmacokinetics of Ibuprofenamine Hydrochloride Spray (NSAIDs), a New Drug for Rheumatoid Arthritis and Osteoarthritis, in Healthy Chinese Subjects. Drug Des. Devel. Ther. 2021, 15, 629–638. [CrossRef]
  32. Chakraborty, S.; Gupta, N.V.; Sastri, K.T.; M, S.; Chand, P.; Kumar, H.; Osmani, R.A.M.; Gowda, D. V; Jain, V. Current Progressions in Transdermal Drug Delivery Systems for Management of Rheumatoid and Osteoarthritis: A Comprehensive Review. J. Drug Deliv. Sci. Technol. 2022, 73, 103476. [CrossRef]
  33. Gupta, V.; Joshi, N.K. Formulation, Development and Evaluation of Ketoprofen Loaded Transethosomes Gel. J. Drug Deliv. Ther. 2022, 12, 86–90. [CrossRef]
  34. Alany, R. Topical and Transdermal Formulation and Drug Delivery. Pharm. Dev. Technol. 2017, 22, 457. [CrossRef]
  35. Sriaandhal Sabalingam; Malitha Aravinda Siriwardhene A Review on Emerging Applications of Emulgel as Topical Drug Delivery System. World J. Adv. Res. Rev. 2022, 13, 452–463. [CrossRef]
  36. Bajaj, S.; Whiteman, A.; Brandner, B. Transdermal Drug Delivery in Pain Management. Contin. Educ. Anaesthesia, Crit. Care Pain 2011, 11, 39–43. [CrossRef]
  37. Skaer, T.L. Dosing Considerations with Transdermal Formulations of Fentanyl and Buprenorphine for the Treatment of Cancer Pain. J. Pain Res. 2014, 7, 495–503. [CrossRef]
  38. Margetts, L.; Sawyer, R. Transdermal Drug Delivery: Principles and Opioid Therapy. Contin. Educ. Anaesth. Crit. Care Pain 2007, 7, 171–176. [CrossRef]
  39. Hu, W.; Bian, Q.; Zhou, Y.; Gao, J. Pain Management with Transdermal Drug Administration: A Review. Int. J. Pharm. 2022, 618, 121696. [CrossRef]
  40. Yang, Y.; Manda, P.; Pavurala, N.; Khan, M.A.; Krishnaiah, Y.S.R. Development and Validation of in Vitro–in Vivo Correlation (IVIVC) for Estradiol Transdermal Drug Delivery Systems. J. Control. Release 2015, 210, 58–66. [CrossRef]
  41. Somayaji, M.R.; Das, D.; Garimella, H.T.; German, C.L.; Przekwas, A.J.; Simon, L. An Integrated Biophysical Model for Predicting the Clinical Pharmacokinetics of Transdermally Delivered Compounds. Eur. J. Pharm. Sci. 2021, 167, 105924. [CrossRef]
  42. Mitragotri, S. Modeling Skin Permeability to Hydrophilic and Hydrophobic Solutes Based on Four Permeation Pathways. J. Control. Release 2003, 86, 69–92. [CrossRef]
  43. Sullivan, S.P.; Murthy, N.; Prausnitz, M.R. Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles. Adv. Mater. 2008, 20, 933–938. [CrossRef]
  44. Wang, F.-Y.; Chen, Y.; Huang, Y.-Y.; Cheng, C.-M. Transdermal Drug Delivery Systems for Fighting Common Viral Infectious Diseases. Drug Deliv. Transl. Res. 2021, 11, 1498–1508. [CrossRef]
  45. Chen, S.; Hanning, S.; Falconer, J.; Locke, M.; Wen, J. Recent Advances in Non-Ionic Surfactant Vesicles (Niosomes): Fabrication, Characterization, Pharmaceutical and Cosmetic Applications. Eur. J. Pharm. Biopharm. 2019, 144, 18–39. [CrossRef]
  46. Escobar-Chávez, J.J.; Bonilla-Martínez, D.; Angélica, M.; Villegas-González; Molina-Trinidad, E.; Casas-Alancaster, N.; Revilla-Vázquez, A.L. Microneedles: A Valuable Physical Enhancer to Increase Transdermal Drug Delivery. J. Clin. Pharmacol. 2011, 51, 964–977. [CrossRef]
  47. Ma, J.; Wang, Y.; Lu, R. Mechanism and Application of Chitosan and Its Derivatives in Promoting Permeation in Transdermal Drug Delivery Systems: A Review. Pharmaceuticals 2022, 15. [CrossRef]
  48. Jain, A.; Mishra, A.; Nayak, S.; Soni, V. Transdermal Delivery of Antihypertensive Agents: A Tabular Update. Int. J. Drug Deliv. 2011, 3. [CrossRef]
  49. Alhodieb, F.S.; Barkat, M.A.; Barkat, H.A.; Ab Hadi, H.; Khan, M.I.; Ashfaq, F.; Rahman, M.A.; Hassan, M.Z.; Alanezi, A.A. Chitosan-Modified Nanocarriers as Carriers for Anticancer Drug Delivery: Promises and Hurdles. Int. J. Biol. Macromol. 2022, 217, 457–469. [CrossRef]
  50. Salama, A.; Badran, M.; Elmowafy, M.; Soliman, G.M. Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies. Pharmaceutics 2020, 12. [CrossRef]
  51. Dhote, V.; Bhatnagar, P.; Mishra, P.K.; Mahajan, S.C.; Mishra, D.K. Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System. Sci. Pharm. 2012, 80, 1–28. [CrossRef]
  52. Park, D.; Park, H.; Seo, J.; Lee, S. Sonophoresis in Transdermal Drug Deliverys. Ultrasonics 2014, 54, 56–65. [CrossRef]
  53. A Charoo, N.; Rahman, Z.; A Repka, M.; N Murthy, S. Electroporation: An Avenue for Transdermal Drug Delivery. Curr. Drug Deliv. 2010, 7, 125–136.
  54. Lavon, I.; Kost, J. Ultrasound and Transdermal Drug Delivery. Drug Discov. Today 2004, 9, 670–676. [CrossRef]
  55. Ng, L.C.; Gupta, M. Transdermal Drug Delivery Systems in Diabetes Management: A Review. Asian J. Pharm. Sci. 2020, 15, 13–25. [CrossRef]
  56. Carter, P.; Narasimhan, B.; Wang, Q. Biocompatible Nanoparticles and Vesicular Systems in Transdermal Drug Delivery for Various Skin Diseases. Int. J. Pharm. 2019, 555, 49–62. [CrossRef]
  57. Kateh Shamshiri, M.; Momtazi-Borojeni, A.A.; Khodabandeh Shahraky, M.; Rahimi, F. Lecithin Soybean Phospholipid Nano-transfersomes as Potential Carriers for Transdermal Delivery of the Human Growth Hormone. J. Cell. Biochem. 2019, 120, 9023–9033.
  58. Barone, A.; Cristiano, M.C.; Cilurzo, F.; Locatelli, M.; Iannotta, D.; Di Marzio, L.; Celia, C.; Paolino, D. Ammonium Glycyrrhizate Skin Delivery from Ultradeformable Liposomes: A Novel Use as an Anti-Inflammatory Agent in Topical Drug Delivery. Colloids Surfaces B Biointerfaces 2020, 193, 111152. [CrossRef]
  59. Serpico, L.; Dello Iacono, S.; De Stefano, L.; De Martino, S.; Battisti, M.; Dardano, P.; Pedatella, S.; De Nisco, M. PH-Sensitive Release of Antioxidant Se-Glycoconjugates through a Flexible Polymeric Patch. Eur. Polym. J. 2022, 178, 111486. [CrossRef]
  60. Tsioris, K.; Raja, W.K.; Pritchard, E.M.; Panilaitis, B.; Kaplan, D.L.; Omenetto, F.G. Fabrication of Silk Microneedles for Controlled-Release Drug Delivery. Adv. Funct. Mater. 2012, 22, 330–335. [CrossRef]
  61. Yu, J.; Xia, Y.; Zhang, H.; Pu, X.; Gong, T.; Zhang, Z.; Deng, L. A Semi-Interpenetrating Network-Based Microneedle for Rapid Local Anesthesia. J. Drug Deliv. Sci. Technol. 2022, 78, 103984. [CrossRef]
  62. Tombs, E.L.; Nikolaou, V.; Nurumbetov, G.; Haddleton, D.M. Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-Sensitive Adhesive (PSA): TEPI® Technology. J. Pharm. Innov. 2018, 13, 48–57. [CrossRef]
  63. Rahmani, F.; Ziyadi, H.; Baghali, M.; Luo, H.; Ramakrishna, S. Electrospun Pvp/Pva Nanofiber Mat as a Novel Potential Transdermal Drug-Delivery System for Buprenorphine: A Solution Needed for Pain Management. Appl. Sci. 2021, 11. [CrossRef]
  64. Kim, K.S.; Ita, K.; Simon, L. Modelling of Dissolving Microneedles for Transdermal Drug Delivery: Theoretical and Experimental Aspects. Eur. J. Pharm. Sci. 2015, 68, 137–143. [CrossRef]
  65. Electrospinning and Crosslinking of Polyvinyl Alcohol/Chitosan Composite Nanofiber for Transdermal Drug Delivery - Cui - 2018 - Advances in Polymer Technology - Wiley Online Library.
  66. Zavareh, H.S.; Pourmadadi, M.; Moradi, A.; Yazdian, F.; Omidi, M. Chitosan/Carbon Quantum Dot/Aptamer Complex as a Potential Anticancer Drug Delivery System towards the Release of 5-Fluorouracil. Int. J. Biol. Macromol. 2020, 165, 1422–1430. [CrossRef]
  67. Qindeel, M.; Ahmed, N.; Sabir, F.; Khan, S.; Ur-Rehman, A. Development of Novel PH-Sensitive Nanoparticles Loaded Hydrogel for Transdermal Drug Delivery. Drug Dev. Ind. Pharm. 2019, 45, 629–641. [CrossRef]
  68. Auda, S.H.; Fathalla, D.; Fetih, G.; El-Badry, M.; Shakeel, F. Niosomes as Transdermal Drug Delivery System for Celecoxib: In Vitro and in Vivo Studies. Polym. Bull. 2016, 73, 1229–1245. [CrossRef]
  69. Say, J.; Tomasco, M.F..; Heller, A.; Gal, Y.; Aria, B.; Heller, E.; Plante, P.J.; Vreeke, M.S.; Friedman, K.A..; Colman, F.C. US 8 617 071 B2 - Analyte Monitoring Device and Method of Use 2013.
  70. Porter, A.L. Forecasting and Management of Technology; John Wiley & Sons, 1991; Vol. 18; ISBN 0471512230.
  71. Speziali, M.G.; Livio, D.F.; Tarabal, V.S.; Granjeiro, P.A. Technology Landscape and a Short Patentometric Review for Antibiofilm Technologies. World Pat. Inf. 2023, 72, 102158. [CrossRef]
  72. Schild, I. Patent or Perish. On the Nature and Role of Patenting amongst Linkoping University Researchers; Working paper, Umea University, Dept of Sociology, 2004.
  73. Ingrole, R.S.J.; Azizoglu, E.; Dul, M.; Birchall, J.C.; Gill, H.S.; Prausnitz, M.R. Trends of Microneedle Technology in the Scientific Literature, Patents, Clinical Trials and Internet Activity. Biomaterials 2021, 267, 120491. [CrossRef]
  74. Azmana, M.; Mahmood, S.; Hilles, A.R.; Mandal, U.K.; Al-Japairai, K.A.S.; Raman, S. Transdermal Drug Delivery System through Polymeric Microneedle: A Recent Update. J. Drug Deliv. Sci. Technol. 2020, 60, 101877. [CrossRef]
  75. Nguyen, Linh C.;Nguyen, An-Dien;Allen Le, K. US 10 303 851 B2 - Physician-Centric Health Care Delivery Platform 2019.
  76. Castel, J.C. US 8 523 791 B2 - Multi-Modal Drug Delivery System 2013.
  77. Searle, Gary; Knapp, Keith N ; Tunkel, Roman; Skutnik, Peter Vedrine, L. US 9 375 529 B2 - Extended Use Medical Device 2016.
  78. Huang, Zhili Joseph; DiPierro, G. US 8 372 040 B2 - Portable Drug Delivery Device Including Detachable and Replaceable Administration or Dosing Element 2013.
  79. Dipierro, G.G.S.A. US 8 252 321 B2 - Biosynchronoustrandermal Drug Delivery for Longevity. Anti-Agin Fatigue Management, Obesity, Weight Loss, Weight Management, Delivery of Nutraceuticals, and the Treatment of Hyperglicemia, Alzheimer’s Disease, Sleep Disorders, Parkinsons 2012.
  80. Yuzhakov, V. V US 7 658 728 B2 - Microneedle Array, Patch, and Applicator for Transdermal Drug Delivery 2010.
  81. de Fougerolles, Antonin; Elbashir, S.M. US 9 186 372 B2 - Split Dose Administration 2008, 2.
  82. Gorman, William; Garibotto, John T.; Flaherthy, J. Christopher; CAI, Amy W.; Dragosits, Thomas, J. WO 2004/060436 A2 - Skin Attachment Apparatus and Method for Patient Infusion Device 2004.
  83. King, G.W.. US 7 206 632 B2 - Patient Sensory Response. Evaluation for Neuromodulation Efficacy Rating 2007.
  84. Bookbinder, Louis H.; Kundu, A.; Frost, G.I. US 7 871 607 B2 - Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases. Syst. methods Robot. gutter Clean. along an axis Rotat. 2011.
  85. Giles-Komar, J.; Knight, D.; Peritt, D.; Mohit, T. WO 2004/39826 A1 - Anti-Il-6 Antibodies, Compositions, Methods and Uses 2004.
  86. Kaplan, L.M..; Ahmad, N.N..; Harris, J.L.; Felder, K.D..; Pastorelli, A. US 11 154 559 B2 - Methods and Compositions of Bile Acids 2021.
  87. Heavner, G.A..; Knight, D.; Ghrayeb, J.; Scallon, B.J..; Nesspor, T.C..; Kutoloski, K.A. WO 2004/002417 A2 - Mammalian CH1 Delected Mimetibodies, Compositions, Mwthods and Uses 2004.
  88. Tomalia, D.A..; Swanson, D.R..; Huang, B.; Pulgam, V.R.; Heinzelmann, R., J.; Svenson, S.; Reyna, L.A..; Chauhan, A.S.; DeMattei, C.R. US 7 985 424 B2 - Dendritic Polymers with Enhanced Amplificatiob and Interior Functionality 2011.
  89. Heavner, G.; Knight, D.M..; Scallon, B.; Ghrayeb, J.; Nesspor, T.C..; Huang, C. WO 2005/032460 A2 - Human Epo Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses 2005.
  90. Tamarkin, D.; Fried-Man, D.; Meir, E. WO 2004/037225 A2 - Cosmetic and Pharmaceutical Foam 2004.
  91. Xu, B. US 7 591 806 B2 - High-Aspect-Ratio Microdevices and Methods for Transdermal Delivery and Sampling of Active Substances 2009.
  92. Heather, D.L..; McCluskie, M.J. WO 01/95935 A1 - Immunostimulatory Nucleic Acids for Inducing a Th2 Immune Response 2001.
  93. Khan, Arifulla; Reinhard, J.F. jr WO2012118562A1 - Compositions and Methods for Treating Depression, Adhd and Other Central Nervous System Disorders Employing Novel Bupropion Compounds, and Methods for Production and Use of Novel Bupropion Compounds and Formulations.
  94. Schøller, J.; Pedersen, H.; Brix, L. US 10 369 204 B2 - Molecular Vaccines for Infectious Disease 2019.
  95. Tamarkin, Dov; Friedman, D.E.M. WO 2005/018530 A2 - Penetrating Pharmaceutical Foam 2005.
  96. Perricone, V.N.; Sayed, Y.A. US 8 668 937 B2 - Topical Nitric Oxide Systems and Methods of Use Thereof 2014.
  97. Ashley, C.E.; Brinker, C.J.; Carnes, E.C.; Fekrazad, M.H.; Felton, L.A.; Negrete, O.; Padilla, D.P.; Wilkinson, B.S.; Wilkinson, D.C.; Willman, C.L. US 2017 / 0232115 A1 - Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery Including Transdermal Delivery of Cargo and Methods Thereof 2017.
Preprints 92333 g001
Figure 1. The data collection and research strategy.
Figure 1. The data collection and research strategy.
Preprints 92333 g001
Preprints 92333 g002
Figure 2. Number of papers per year.
Figure 2. Number of papers per year.
Preprints 92333 g002
Preprints 92333 g004
Figure 4. The co-authorship network of Countries in TDD studies.
Figure 4. The co-authorship network of Countries in TDD studies.
Preprints 92333 g004
Preprints 92333 g005
Figure 5. The co-occurrence cluster analysis of the top keywords in TDD papers.
Figure 5. The co-occurrence cluster analysis of the top keywords in TDD papers.
Preprints 92333 g005
Preprints 92333 g006
Figure 6. The number of TDD patent applications in the years.
Figure 6. The number of TDD patent applications in the years.
Preprints 92333 g006
Preprints 92333 g007
Figure 7. A) Total strength of the co-occurrence links between keywords in TDD patents; B) co-occurrence cluster analysis of the top of TDD patents keywords over the time.
Figure 7. A) Total strength of the co-occurrence links between keywords in TDD patents; B) co-occurrence cluster analysis of the top of TDD patents keywords over the time.
Preprints 92333 g007
Preprints 92333 g008
Figure 8. Total link strength of top ten keywords in title/abstract/keyword of the recovered patents.
Figure 8. Total link strength of top ten keywords in title/abstract/keyword of the recovered patents.
Preprints 92333 g008
Preprints 92333 g009
Figure 9. Scientific papers and patents production on TDD for year.
Figure 9. Scientific papers and patents production on TDD for year.
Preprints 92333 g009
Table 1. The top 10 journals in publishing papers on TDD.
Table 1. The top 10 journals in publishing papers on TDD.
Rank  Source IF (2022)  Total publications
 (Percentage)		 Total Citations
1 International Journal of Pharmaceutics 6.270 525 (6.7 %) 23,596
2 Journal Of Controlled Release 11.467 262 (3.4 %) 19,315
3 Journal Of Pharmaceutical Sciences 3.534 226 (2.9 %) 6,606
4 Drug Development and Industrial Pharmacy 3.225 178 (2.3 %) 4,365
5 AAPS Pharmscitech 3.246 158 (2.0 %) 4,451
6 Journal Of Drug Delivery Science and Technology 3.981 155 (2.0 %) 1,837
7 Pharmaceutical Research 4.580 153 (2.0 %) 7,893
8 Pharmaceutics 6.072 135 (1.7 %) 1,724
9 European Journal of Pharmaceutics and Biopharmaceutics 5.589 126 (1.6 %) 6,486
10 Drug Delivery 6.420 122 (1.6 %) 2,462
Table 2. The top 10 highest cited articles on TDD.
Table 2. The top 10 highest cited articles on TDD.
Title PY Journal Citations Ref.
Biomedical applications of collagen 2001 International Journal of Pharmaceutics 1,516 [16]
Penetration enhancers 2012 Advanced Drug Delivery Reviews 1,509 [17]
Microneedles for transdermal drug delivery 2004 Advanced Drug Delivery Reviews 1,102 [18]
Ethosomes - Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties 2000 Journal of Controlled Release 1,044 [19]
Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery 2005 Journal of Controlled Release 693 [20]
Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module 2017 Science Advances 679 [21]
Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies 2003 Proceedings of the National Academy of Sciences of the United States of America 658 [22]
Iontophoretic drug delivery 2004 Advanced Drug Delivery Reviews 641 [23]
Dissolving microneedles for transdermal drug delivery 2008 Biomaterials 639 [24]
Lipid vesicles and other colloids as drug carriers on the skin 2004 Advanced Drug Delivery Reviews 573 [25]
Table 3. The top 10 authors of papers on TDD.
Table 3. The top 10 authors of papers on TDD.
Author Name Country Affiliation Documents count
Banga, A.K. United States University of Atlanta 78
Donnelly, R.F. Ireland Queen’s University Belfast 75
Prausnitz, M.R. United States Georgia Institute of Technology 69
Kalia, Y.N. Suisse Université de Genève 61
Fang, L. China Shenyang Pharmaceutical University 58
Mitragotri, S. United States Georgia Institute of Technology 50
Aqil, M. Saudi Arabia King Saud University 49
Stinchcomb, A.L. United States University of Maryland School of Pharmacy 46
Opanasopit, P. Thailand Silpakorn University 38
Shin, S.C. South Korea Chonnam National University 38
Table 4. Top 10 public funding sponsors in TDD field.
Table 4. Top 10 public funding sponsors in TDD field.
Funding Sponsor Country Documents count
National Natural Science Foundation China 469
National Institutes of Health United States 237
National Research Foundation Korea 117
National Institute of Biomedical Imaging and Bioengineering United States 79
Fundamental Research Funds for the Central Universities China 74
Japan Society for the Promotion of Science Japan 72
Conselho Nacional de Desenvolvimento Científico e Tecnológico Brasil 70
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Brasil 70
National Science Foundation United States 70
Ministry of Education, Culture, Sports, Science and Technology Japan 64
Table 5. Top 10 thematic area on which TDD impacts.
Table 5. Top 10 thematic area on which TDD impacts.
Subject Area Documents count
Pharmacology, Toxicology and Pharmaceutics 4,778
Medicine 1,790
Biochemistry, Genetics and Molecular Biology 1,553
Chemistry 1,337
Materials Science 1,132
Engineering 852
Chemical Engineering 791
Physics 509
Immunology and Microbiology 134
Multidisciplinary 124
Table 6. Clusters of the top 92 keywords occurring in papers on TDD.
Table 6. Clusters of the top 92 keywords occurring in papers on TDD.
Keywords
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6
anti-inflammatory
curcumin
diclofenac sodium
dissolving MNs
ethosome
hyaluronic acid
hydrogel
ibuprofen
in vitro release
indomethacin
ketoprofen
liposome
meloxicam
methotrexate
microemulsion
nanoemulsion
nanoparticle		 nanostructured lipid carriers
oleic acid
penetration enhancer
percutaneous absorption
psoriasis
rheumatoid arthritis
skin irritation
skin penetration
skin permeability
skin permeation
solid lipid nanoparticles stability
stratum corneum
sustained release
topical delivery
transdermal absorption
transdermal permeation		 bioavailability
buprenorphine enhancer
estradiol
fentanyl
human skin
lidocaine
microdialysis
pain
patch
pharmacodynamics
pharmacokinetic
transdermal administration
transdermal delivery system
transdermal patch		 absorption
controlled release
diclofenac
diffusion
drug delivery systems
formulation
hydrogels
mathematical model
percutaneous
permeability
protein delivery
skin
solubility
surfactants		 chitosan
drug release flux
hypertension
in vitro
in vivo
nanoparticles
permeation
permeation enhancer
release
topical
transdermal
transdermal patches		 diabetes
drug delivery
electroporation
insulin
iontophoresis
microneedles
sonophoresis
ultrasound		 ethosomes
factorial design
gel
liposomes
niosomes
optimization
proniosomes
transfersomes
Table 7. Some examples of TDD systems reported in published articles.
Table 7. Some examples of TDD systems reported in published articles.
Drug/prodrug/NPs Released Methods of Preparation and Formulation Details System Operation Inference Cluster Ref.
Ammonium glycyrrhizinate (A.G.) Ammonium glycyrrhizinate - ultra-deformable liposomes (A.G.-ULs) were obtained by dissolving the drug in the lipid components during the synthesis of ULs (thin-layer evaporation technique) High dimensional stable ULs pass intact through the skin and deliver AG in specific tissues in a controlled manner Anti-inflammatory effect 6 [58]
Resveratrol/ caffeic acid containing glycoconjugates Imbibition of PEGDA/HEMA films in water solution containing the glycoconjugates pH-dependent release of synthetic selenium-containing glycoconjugates Antioxidant effect, potential wound healing acceleration 3 [59]
Horseradish peroxidase (HRP) enzyme Silk MNs obtained by aqueous-based micro-molding and simultaneous loading with HRP The degradation rate of silk fibroin and the diffusion rate of the entrained molecules can be controlled by adjusting post-processing conditions Tunable release kinetics 5 [60]
Lidocaine hydrochloride (LIDH) UV crosslinked methacrylated chondroitin sulfate (CS-MA) and polyvinylpyrrolidone (PVP) K29/32MNs loaded with LIDH At body temperature PVP K29/32 rapidly dissolve, with subsequent release of LIDH Local anesthesia 5 [61]
Ibuprofenamine hydrochloride (2-(Diethylamino) ethyl 2-(4-isobutylphenyl) propionate hydrochloride Clinical trial research, in which spray Ibuprofenamine hydrochloride penetrates the skin and biological barrier into the lesion tissue after administration Spray Ibuprofenamine hydrochloride (prodrug of ibuprofen) penetrates the skin and is quickly converted into therapeutic ibuprofen Anti-inflammatory effect 1 [31]
Ibuprofen Hot-melt poly(ether-urethane)-silicone crosslinked pressure-sensitive adhesive (HMPSAs) drug reservoir formation Adhesive matrix releases ibuprofen that penetrates the skin. The presence of chemical enhancers, di(ethylene) glycol monoethyl ether (DEGEE), facilitates the API penetration Anaesthetic in case of moderate pain 1 [62]x
Buprenorphine hydrochloride (Bup) Electrospinning of poly (vinyl pyrrolidone) (PVP) and a blend of 50/50 W/W of buprenorphine-loaded poly(vinyl alcohol (PVA) and PVP polymer solutions in water, used as a drug carrier for buprenorphine (Bup): (Bup/PVP) and(Bup/PVP/PVA) Bup-loaded crosslinked nanofibers improve carrier retention and provide a controlled release of Bup Controlled release 2 [63]
Fentanyl citrate Sucrose based MN model are made from a water-soluble matrix, premixed with fentanyl citrate Dissolving MNs are submerged in a rectangular compartment. The top and the bottom of the compartment represent the SC and the bloodstream, respectively. Once an MN patch is applied to the skin, the needles penetrate the dermis and begin to dissolve. Controlled release 2 [64]
Ampicillin sodium Polyvinyl alcohol (PVA)/ chitosan (CS) composite nanofibers are fabricated by electrospinning, and then crosslinked through glulataraldehyde (GA) Crosslinked PVA/CS composite nanofibers have a lower drug release rate and a smaller amount of drug burst release than that of PVA/CS, showing potential as TDD system Controlled release of drugs 4 [65]
5-FU anti-cancer drug 5-fluorouracil-chitosan-carbon quantum dot-aptamer (5-FU-CS-CQD-Apt) nanoparticle is synthesized owing to W/O emulsification method 5-FU-CS-CQD-Apt shows a pH-sensitive and sustained drug release profile Release of the drug in a controlled manner 4 [66]
Piroxicam Nanoprecipitation technique is used for preparation of drug loaded Eudragit S100 (ES100)/NPs. ES100 as a nanocarrier for transdermal delivery of Piroxicam pH-sensitive permeation 3 [67]
Celecoxib (CXB) CXB niosomes by thin film hydration method The release of CXB from different niosomal gel formulations (Span 60 or Span 40 and cholesterol) depends on the viscosity of the prepared gels Anti-inflammatory activity of the drug from niosomal gel formulations 1,6 [68]
Table 8. TOP 10 countries in which patents on TDD have been filed or granted.
Table 8. TOP 10 countries in which patents on TDD have been filed or granted.
Jurisdiction Documents Count
United States 3,002
China 793
European Patents 608
Canada 268
Korea, Republic of 222
Australia 207
Japan 90
Mexico 84
Taiwan 68
United Kingdom 37
Table 9. TOP 10 Cooperative Patent Classification in TDD field.
Table 9. TOP 10 Cooperative Patent Classification in TDD field.
CPC %
A61K9/0014 10.6
A61K9/7061 8.2
A61P29/00 6.0
A61M37/0015 5.8
A61K9/7084 5.8
A61P35/00 5.4
A61K47/10 5.3
A61K45/06 4.9
A61P43/00 4.7
A61P25/00 4.5
Table 11. TOP 10 cited active patents that refer to a medical device comprising a housing for TDD.
Table 11. TOP 10 cited active patents that refer to a medical device comprising a housing for TDD.
Application Number Application Date Title Owners Rif
US 10 303 851 B2 14/03/2014 Physician-centric health care delivery platform HANA PATENT TECHNOLOGY LLC [75]
US 8 523 791 B2 11/08/2009 Multi-modal drug delivery system CAREWEAR CORP [76]
US 9 375 529 B2 02/09/2009 Extended use medical device BECTON DICKINSON AND COMPANY [77]
US 8 372 040 B2 24/05/2006 Portable drug delivery device including a detachable and replaceble administration or dosing element CHRONO THERAPEUTICS INC [78]
US 8 617 071 B2 31/10/2006 Analyte monitoring device and methods of use ABBOTT DIABETES CARE INC [69]
US 8 252 321 B2 31/10/2007 Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer’s disease, sleep disorders, parkinson’s disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like CHRONO THERAPEUTICS INC [79]
US 7 658 728 B2 10/01/2006 Microneedle array, patch, and applicator for transdermal drug delivery YUZHAKOV VADIM V [80]
US 9 186 372 B2 21/05/2013 Split dose administration MODERNA THERAPEUTICS [81]
WO 2004/060436 A2 04/12/2003 Skin attachament apparatus and method for patient infusion device INSULET CORP [82]
US 7 206 632 B2 30/01/2004 Patient sensory response evaluation for neuromodulation efficacy rating MEDTRONIC INC [83]
Table 12. TOP 10 cited active patents that refer to TDD for the treatment of cancer.
Table 12. TOP 10 cited active patents that refer to TDD for the treatment of cancer.
Application Number Application Date Title Owners Note on TDD Ref.
US 7 871 607 B2 23/02/2005 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases HALOZYME INC Novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture and administration (including TDD) that can be applied to enhance the bioavailability (and potentially improve other pharmacokinetic and / or pharmacodynamic properties) of pharmacologic and other agents that are useful for treating or diagnosing various disease conditions [84]
WO 2004/39826 A1 26/10/2002 Anti-il-6 antibodies, compositions, methods and uses CENTOCOR INC Transdermal administration of anti-IL-6 antibody encapsulated in a delivery device such as a liposome or polymeric nanoparticles, microparticle, microcapsule, or microspheres (referred to collectively as microparticles unless otherwise stated) [85]
US 11 154 559 B2 28/09/2012 Methods and compositions of bile acids GEN HOSPITAL CORP A carrier that protects the composition against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems [86]
WO 2004/002417 A2 27/06/2003 Mammalian CH1 deleted mimetibodies, compositions, methods and uses CENTOCOR INC CH1-deleted mimetibody or specified portion or variant in either the stable or preserved formulations or solutions described, can be administered via a variety of delivery methods including TDD [87]
US 7 985 424 B2 21/12/2005 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC Dendritic polymers can have utility in many application (in vivo diagnostic imaging, drug delivery, drug discovery, in vitro diagnostics, coatings for medical devices, anti-biofouling coatings, TDD, chemotherapies, NIR absorbers, magnetic bioreactor, etc. [88]
WO 2005/032460 A2 03/09/2004 Human epo mimetic hinge core mimetibodies, compositions, methods and uses CENTOCOR INC Mammalian EPO mimetic hinge core mimetibodies that can be used by contacting or administering by at least one mode comprising TDD [89]
WO 2004/037225 A2 24/10/2003 Cosmetic and pharmaceutical foam FOAMIX LTD Alcohol-free, pharmaceutical foam carrier and its use [90]
US 7 591 806 B2 18/05/2005 High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances XU BAI High-aspect-ratio microdevices (including microneedles) and the method of making and using the same, for TDD [91]
WO 01/95935 A1 22/01/2001 Immunostimulatory nucleic acids for inducing a th2 immune response OTTAWA HEALTH RESEARCH INST The compounds can be administered to the skin, e.g., topically in the form of a skin cream, by injection, or any other method of administration where access to the skin cells and/or target APCs by the compounds is obtained [92]
US 8 372 040 B2 22/01/2001 Portable drug delivery device including a detachable and replaceable administration or dosing element CHRONO THERAPEUTICS INC A device for TDD and administration of differing dosages at specific times of the day automatically pursuant to a pre-programmed dosage profile [78]
Table 13. TOP 10 cited active patents that refer to TDD for the administration of prodrugs.
Table 13. TOP 10 cited active patents that refer to TDD for the administration of prodrugs.
Application
Number		 Application
Date		 Title Owners Note Ref.
US 7 871 607 B2 23/02/2005 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases HALOZYME INC Novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture and administration (including TDD) that can be applied to enhance the bioavailability (and potentially improve other pharmacokinetic and / or pharmacodynamic properties) of pharmacologic and other agents that are useful for treating or diagnosing various disease conditions [84]
US 7 985 424 B2 21/12/2005 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC Dendritic polymers can have utility in many application (in vivo diagnostic imaging, drug delivery, drug discovery, in vitro diagnostics, coatings for medical devices, anti-biofouling coatings, TDD, chemotherapies, NIR absorbers, magnetic bioreactor, etc. [88]
WO2012118562A1 02/03/2012 Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations RHINE PHARMACEUTICALS LLC Compositions and methods are disclosed using a purified (R)(-) enantiomer of bupropion (including prodrug) to treat central nervous system disorders [93]
WO 2004/037225 A2 24/10/2003 cosmetic and pharmaceutical foam FOAMIX LTD Alcohol-free, pharmaceutical foam carrier and its use [90]
US 8 523 791 B2 11/08/2009 Multi-modal drug delivery system CAREWEAR CORP A device for the transdermal delivery of a therapeutic agent at a treatment site comprising a mechanical vibration element, a light source, and a heating and/or cooling element [76]
WO 01/95935 A1 22/01/2001 Immunostimulatory nucleic acids for inducing a th2 immune response OTTAWA HEALTH RESEARCH INST The compounds can be administered to the skin, e.g., topically in the form of a skin cream, by injection, or any other method of administration where access to the skin cells and/or target APCs by the compounds is obtained [92]
US 10 369 204 B2 02/10/2009 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES INC Methods for construction of pharmamers, i.e., vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules [94]
WO 2005/018530 A2 20/08/2004 Penetrating pharmaceutical foam FOAMIX LTD Alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration [95]
US 8 668 937 B2 17/03/2012 Topical nitric oxide systems and methods of use thereof TRANSDERMAL BIOTECHNOLOGY INC Compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface [96]
US 2017 / 0232115 A1 12/10/2012 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof SANDIA CORP The protocells enhance SC permeability and enable transdermal delivery of active ingredients including macromolecules [97]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated